基于属性层次模型结合加权优劣解距离法的利妥昔单抗药物利用评价  

Drug Utilization Evaluation of Rituximab Based on Attribute Hierarchy Model Combined with Weighted TOPSIS Method

作　　者：程赛赛 刘洪峰[1] 孟现奇 周碧 朱峰[2] CHENG Saisai;LIU Hongfeng;MENG Xianqi;ZHOU Bi;ZHU Feng(Dept.of Pharmacy,Suzhou Hospital of Anhui Medical University,Anhui Suzhou 234000,China;Dept.of Pediatrics,Suzhou Hospital of Anhui Medical University,Anhui Suzhou 234000,China)

机构地区：[1]安徽医科大学附属宿州医院药剂科,安徽宿州234000 [2]安徽医科大学附属宿州医院儿科,安徽宿州234000

出　　处：《中国医院用药评价与分析》2025年第2期207-210,214,共5页Evaluation and Analysis of Drug-use in Hospitals of China

基　　金：2023年安徽省临床医学研究转化专项(No.202304295107020119)。

摘　　要：目的:建立利妥昔单抗临床合理应用评价体系,为临床合理用药提供参考。方法:参照相关药品说明书、临床指南和专家共识等,制定利妥昔单抗药物利用评价(DUE)细则,使用属性层次模型(AHM)结合加权优劣解距离法(TOPSIS),对2023年1月至2024年6月该院204例患者病历中利妥昔单抗的使用情况进行合理性评价。结果:204份病历中,相对接近度(C_(i))为50.59%~100.00%;其中,C_(i)为50%~<60%的有14份(占6.86%),C_(i)为60%~<70%的有45份(占22.06%),C_(i)为70%~<80%的有70份(占34.31%),C_(i)为80%~<90%的有49份(占24.02%),C_(i)为100.00%的有26份(占12.75%)。不合理主要集中在病程记录、注意事项、不良反应监测与处置、预处理、给药速度和适应证等方面。结论:所建立的利妥昔单抗DUE标准可用于利妥昔单抗的临床应用合理性评价。该院利妥昔单抗的使用存在较多不规范之处,需要加强对临床的干预。OBJECTIVE:To establish an evaluation system for rational clinical use of rituximab injection,so as to provide reference for rational clinical drug use.METHODS:According to the relevant drug instructions,clinical guidelines and expert consensus,the drug utilization evaluation(DUE)for rituximab injection were formulated.The attribute hierarchy model(AHM)combined with weighted technique for order preference by similarity to an ideal solution(TOPSIS)was used to evaluate the rationality of rituximab in 204 medical records in the hospital from Jan.2023 to Jun.2024.RESULTS:Among the 204 medical records,the relative proximity(C_(i))was from 50.59%to 100.00%.There were 14 cases(6.86%)with 50%≤C_(i)<60%,45 cases(22.06%)with 60%≤C_(i)<70%,70 cases(34.31%)with 70%≤C_(i)<80%,and 49 cases(24.02%)with 80%≤C_(i)<90%;there were 26(12.75%)with C_(i)of 100.00%.The irrationality mainly focused on the course record,precautions,adverse drug reactions monitoring and treatment,pre-treatment,administration frequency and indications.CONCLUSIONS:The established DUE criteria of rituximab can be used to evaluate the rationality of clinical use of rituximab.There are many irregularities in the use of rituximab in the hospital,and it is necessary to strengthen clinical intervention.

关 键 词：利妥昔单抗 药物利用评价 属性层次模型 加权优劣解距离法 合理用药 

分 类 号：R979.1[医药卫生—药品]